Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. reduced its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 17.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 172,879 shares of the company’s stock after selling 36,608 shares during the quarter. Victory Capital Management Inc. owned approximately 0.61% of Krystal Biotech worth $21,447,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in KRYS. Commonwealth Equity Services LLC grew its position in Krystal Biotech by 2.5% during the third quarter. Commonwealth Equity Services LLC now owns 4,426 shares of the company’s stock valued at $513,000 after acquiring an additional 110 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in Krystal Biotech by 10.4% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,007 shares of the company’s stock valued at $349,000 after acquiring an additional 283 shares during the period. Deutsche Bank AG grew its position in Krystal Biotech by 2.8% during the third quarter. Deutsche Bank AG now owns 13,499 shares of the company’s stock valued at $1,566,000 after acquiring an additional 365 shares during the period. EAM Investors LLC grew its position in Krystal Biotech by 2.4% during the third quarter. EAM Investors LLC now owns 16,091 shares of the company’s stock valued at $1,867,000 after acquiring an additional 377 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its position in Krystal Biotech by 111.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company’s stock valued at $83,000 after acquiring an additional 379 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Stock Performance

NASDAQ:KRYS opened at $158.74 on Friday. Krystal Biotech, Inc. has a one year low of $86.03 and a one year high of $189.97. The business’s 50-day simple moving average is $168.75 and its 200 day simple moving average is $134.44. The stock has a market cap of $4.53 billion, a price-to-earnings ratio of 84.89 and a beta of 0.91.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, May 6th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.20 by ($0.17). The company had revenue of $45.25 million during the quarter, compared to analyst estimates of $47.37 million. During the same quarter last year, the business posted ($1.76) EPS. The business’s quarterly revenue was up 452400.0% on a year-over-year basis. On average, equities research analysts predict that Krystal Biotech, Inc. will post 1.82 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on KRYS shares. Guggenheim upped their target price on Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 target price on shares of Krystal Biotech in a research report on Monday. Stifel Nicolaus reaffirmed a “buy” rating and issued a $204.00 target price (up previously from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. Citigroup upped their target price on Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Finally, William Blair reaffirmed an “outperform” rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, Krystal Biotech presently has an average rating of “Buy” and an average price target of $171.00.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total transaction of $829,400.00. Following the sale, the chief accounting officer now owns 12,936 shares in the company, valued at $2,145,823.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the sale, the insider now owns 1,550,882 shares in the company, valued at $265,138,786.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Kathryn Romano sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total value of $829,400.00. Following the sale, the chief accounting officer now owns 12,936 shares in the company, valued at approximately $2,145,823.68. The disclosure for this sale can be found here. Insiders have sold 38,087 shares of company stock worth $6,210,591 over the last quarter. 14.10% of the stock is owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).